Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206371 | 0.88 | S1PR1 (0.39) | FFAR4FFAR1MAPTRXFP1S1PR2 | |
| SCHEMBL26206475 | 0.88 | S1PR2 (0.37) | FFAR4FFAR1MAPTRXFP1S1PR2 | |
| SCHEMBL26206459 | 0.83 | FFAR1 (0.47) | FFAR1MAPTRXFP1S1PR2S1PR1 | |
| SCHEMBL26206404 | 0.82 | LTB4R (0.37) | TSHRFFAR4FFAR1MAPTRXFP1 | |
| SCHEMBL26206374 | 0.81 | PPARA (0.51) | FFAR1MAPTRXFP1 | |
| SCHEMBL22526998 | 0.81 | AAK1 (0.42) | TSHRFFAR4FFAR1 | |
| SCHEMBL26206478 | 0.80 | FOS (0.38) | TSHR | |
| SCHEMBL26206480 | 0.80 | FFAR4 (0.39) | FFAR4FFAR1MAPTRXFP1S1PR2 | |
| SCHEMBL26205965 | 0.79 | TSHR (0.43) | TSHRFFAR4FFAR1 | |
| SCHEMBL26205641 | 0.77 | AAK1 (0.38) | TSHRBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | TSHR 1768/4885FFAR4 3503/4885FFAR1 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.